ArticleBiomedical reports2017
Personalized medicine could transform healthcare.
Article in Biomedical reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 144 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
144 citing papers in PubMed, 2 syntheses or guidelines pooled it, 358 citations in OpenAlex.
- Impact of Decision Aids for Shared Decision-Making for Patients with Early Stage Breast Cancer: A Systematic Review.Current oncology (Toronto, Ont.) · 2026Pooled it
- Potentiality of algorithms and artificial intelligence adoption to improve medication management in primary care: a systematic review.BMJ open · 2023Pooled it
- Detection of an anti-angina therapeutic module in the effective population treated by a multi-target drug Danhong injection: a randomized trial.Signal transduction and targeted therapy · 2021Trial
- 3D bioprinting technologies and biomaterial-based scaffolds for wound healing: Insights into decellularized tissue-derived bioinks.Regenerative therapy · 2026Review
- A Review of Virtual Twins in Physiologically-Based Pharmacokinetic Modeling and Simulation.Clinical pharmacology and therapeutics · 2026Review
- Tumoral switch in NUMB splicing changes essential transcription pathways and induces malignant properties in tumour cells.Genome biology · 2026Article
- Personalized medicine as a novel therapeutic approach for autoimmune diseases: new insights and future prospects.Osong public health and research perspectives · 2026Article
- Review
- Artificial Intelligence For 6P Medicine: Consolidating AI Needs of Predictive, Preventive, Personalized, Participatory, Precision, and Public Health Trajectories.Journal of medical systems · 2026Review
- Digital Health as an Enabler of Personalized Medicine in Ghana: Gaps, Opportunities, and Future Directions.Journal of medical Internet research · 2026Article
- Value drivers and barriers to the adoption of Precision Psychiatry in Latin America: a qualitative study.BMC psychiatry · 2026Article
- Emerging CRISPR Approaches for Countering Immune Evasion: Insight from Recent Studies.International journal of molecular sciences · 2026Review
- Serum biomarkers as personalised medicine for diagnostic and therapeutic approaches of hepatocellular carcinoma.Journal of the Egyptian National Cancer Institute · 2026Review
- Article
- Industry-defined opportunities for advancing big data capabilities in biopharmaceutical manufacturing.Frontiers in bioengineering and biotechnology · 2026Review
- Customized Marketing Strategies for Cancer Immunocyte Therapy Based on its Distinctive Attributes.Cancer management and research · 2026Review
- Advances in Nose-to-Brain Delivery Systems for Effective Alzheimer's Disease Management.Current Alzheimer research · 2026Review
- Navigating Antimicrobial Resistance Insights: An In-Depth Analysis of Healthcare Providers' Knowledge, Attitudes, and Practices, with an Emphasis on Precision Medicine in Pakistan.Antibiotics (Basel, Switzerland) · 2025Article
- PatientProfiler: building patient-specific signaling models from proteogenomic data.Molecular systems biology · 2025Article
- Article
84 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Personalized medicine (PM) is about tailoring a treatment as individualized as the disease. The approach relies on identifying genetic, epigenomic, and clinical information that allows the breakthroughs in our understanding of how a person's unique genomic portfolio makes them vulnerable to certain diseases. PM approach is a complete extension of traditional approach (One-Size-Fits-All) to increasing our ability to predict which medical treatments will be safe and effective for individual patient, and which ones will not be, based on the patient's unique genetic profile. Implementation of PM has the potential to reduce financial and time expenditure, and increase quality of life and life extension of patients. Knowledge of PM facilitates earlier disease detection via enhanced use of existing biomarkers and detection of early genomic and epigenomic events in disease development, particularly carcinogenesis. The PM approach predominantly focuses on preventative medicine and favours taking pro-active actions rather than just reactive. This approach delays or prevents the need to apply more severe treatments which are usually less tolerated and with increased quality of life and financial considerations. Increasing healthcare costs have placed additional pressure on government funded healthcare systems globally, especially regarding end of life care. PM may increase the effectiveness of existing treatments and negate the inherent problems associated with non-PM approaches. PM is a young but rapidly expanding field of healthcare where a physician can select a treatment based on a patient's genetic profile that may not only minimize harmful side effects and guarantee a more successful result, but can be less cost effective compared with a 'trial-and-error' approach to disease treatment. The less efficient non-PM ('trial-and-error') approach, which can lead to drug toxicity, severe side effects, reactive treatment and misdiagnosis continue to contribute to increasing healthcare costs. Increased patient stratification will allow for the enhanced application of PM and pro-active treatment regimens, resulting in reduced costs and quality of life enhancement.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.